RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Newron Pharmaceuticals SpA Stock

Newron Pharmaceuticals SpA EBIT 2024

Newron Pharmaceuticals SpA EBIT

5.44 M EUR

Ticker

NWRN.SW

ISIN

IT0004147952

WKN

A0LF18

In 2024, Newron Pharmaceuticals SpA's EBIT was 5.44 M EUR, a -146.75% increase from the -11.63 M EUR EBIT recorded in the previous year.

The Newron Pharmaceuticals SpA EBIT history

YEAREBIT (undefined EUR)
2029e-
2028e163.29
2027e96.35
2026e3.49
2025e1.89
2024e5.44
2023-11.63
2022-13.3
2021-12.36
2020-18.07
2019-20.9
2018-14.98
2017-4.1
2016-15.33
2015-24.4
2014-11.22
2013-7.78
2012-2.7
2011-6.48
2010-21.64
2009-24.56
2008-18.32
2007-13.68
2006-16.75
2005-15.08
2004-12.22

Newron Pharmaceuticals SpA Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Newron Pharmaceuticals SpA, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Newron Pharmaceuticals SpA from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Newron Pharmaceuticals SpA’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Newron Pharmaceuticals SpA. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Newron Pharmaceuticals SpA’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Newron Pharmaceuticals SpA’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Newron Pharmaceuticals SpA’s growth potential.

Newron Pharmaceuticals SpA Revenue, EBIT and net profit per share

DateNewron Pharmaceuticals SpA RevenueNewron Pharmaceuticals SpA EBITNewron Pharmaceuticals SpA Net Income
2029e202.85 M undefined0 undefined0 undefined
2028e193.72 M undefined163.29 M undefined109.84 M undefined
2027e123.74 M undefined96.35 M undefined68.39 M undefined
2026e20.68 M undefined3.49 M undefined785,763.14 undefined
2025e22.02 M undefined1.89 M undefined1.38 M undefined
2024e22.78 M undefined5.44 M undefined720,348.36 undefined
20239.06 M undefined-11.63 M undefined-16.22 M undefined
20226.09 M undefined-13.3 M undefined-17.49 M undefined
20215.76 M undefined-12.36 M undefined-14.9 M undefined
20205.26 M undefined-18.07 M undefined-21 M undefined
20197.04 M undefined-20.9 M undefined-20.21 M undefined
20184.03 M undefined-14.98 M undefined-15.04 M undefined
201713.29 M undefined-4.1 M undefined-5.28 M undefined
20164.74 M undefined-15.33 M undefined-15.24 M undefined
20152.28 M undefined-24.4 M undefined-22.82 M undefined
20141.3 M undefined-11.22 M undefined-10.1 M undefined
20133.21 M undefined-7.78 M undefined-7.1 M undefined
20128.91 M undefined-2.7 M undefined-2.38 M undefined
2011280,000 undefined-6.48 M undefined-6.45 M undefined
2010630,000 undefined-21.64 M undefined-20.55 M undefined
2009950,000 undefined-24.56 M undefined-23.48 M undefined
20082.64 M undefined-18.32 M undefined-16.36 M undefined
20074.02 M undefined-13.68 M undefined-11.09 M undefined
20061.19 M undefined-16.75 M undefined-16.4 M undefined
20050 undefined-15.08 M undefined-14.92 M undefined
200480,000 undefined-12.22 M undefined-12.15 M undefined

Newron Pharmaceuticals SpA stock margins

The Newron Pharmaceuticals SpA margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Newron Pharmaceuticals SpA. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Newron Pharmaceuticals SpA.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Newron Pharmaceuticals SpA's sales revenue. A higher gross margin percentage indicates that the Newron Pharmaceuticals SpA retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Newron Pharmaceuticals SpA's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Newron Pharmaceuticals SpA's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Newron Pharmaceuticals SpA's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Newron Pharmaceuticals SpA. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Newron Pharmaceuticals SpA's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Newron Pharmaceuticals SpA Margin History

Newron Pharmaceuticals SpA Gross marginNewron Pharmaceuticals SpA Profit marginNewron Pharmaceuticals SpA EBIT marginNewron Pharmaceuticals SpA Profit margin
2029e94.8 %0 %0 %
2028e94.8 %84.29 %56.7 %
2027e94.8 %77.87 %55.27 %
2026e94.8 %16.87 %3.8 %
2025e94.8 %8.56 %6.24 %
2024e94.8 %23.86 %3.16 %
202394.8 %-128.4 %-179.13 %
202292.73 %-218.28 %-287.05 %
202197.97 %-214.46 %-258.61 %
202094.39 %-343.59 %-399.35 %
201979.75 %-296.95 %-287.11 %
201865.91 %-372.12 %-373.54 %
201788.14 %-30.83 %-39.76 %
201644.4 %-323.52 %-321.66 %
201544.53 %-1,072.53 %-1,002.9 %
201463.31 %-862.69 %-776.54 %
201391.59 %-242.37 %-221.18 %
201294.8 %-30.3 %-26.71 %
201194.8 %-2,314.29 %-2,303.57 %
201094.8 %-3,434.92 %-3,261.9 %
200994.8 %-2,585.26 %-2,471.58 %
200894.8 %-693.94 %-619.7 %
200794.8 %-340.3 %-275.87 %
200694.8 %-1,407.56 %-1,378.15 %
200594.8 %0 %0 %
200494.8 %-15,275 %-15,187.5 %

Newron Pharmaceuticals SpA Aktienanalyse

What does Newron Pharmaceuticals SpA do?

Newron Pharmaceuticals SpA is an international biopharmaceutical company specializing in the development of novel products for the treatment of central nervous system (CNS) disorders. The company is headquartered in Italy and is listed on the SIX Swiss Exchange. The history of Newron Pharmaceuticals SpA dates back to 1996 when it was founded by a team of experienced pharmaceutical experts. Since then, the company has become a leading player in the development of therapies for rare neurological disorders. The focus is particularly on diseases such as Parkinson's and Rett syndrome, as well as other neurological disorders. Newron Pharmaceuticals SpA's business model is based on the research and development of novel drugs in the field of the central nervous system. The company typically conducts research and development in its own laboratories and collaborates closely with external experts and institutions to develop innovative therapies. The goal is to develop patient-oriented, innovative drugs and successfully bring them to market. The company has several product candidates in various stages of development, including Xadago® (Safinamide), an approved drug for the treatment of Parkinson's. Similarly, an orally administered drug is being tested in phase III of clinical development with the aim of improving motor symptoms in Parkinson's. Another important product candidate of Newron Pharmaceuticals SpA is Sarizotan, an innovative drug for the treatment of Rett syndrome, a rare neurological disease that primarily affects girls. The company has entered into a partnership with the American company Rett Syndrome Research Trust (RSRT) to promote further development of the drug. In addition to researching and developing new drugs, Newron also actively works on advancing existing treatment approaches. For example, collaborations with academic institutions are used to incorporate new knowledge from the fields of molecular biology and genetics to further expand existing therapeutic approaches. The company follows an integrative approach, focusing on collaboration between research and development teams, clinical experts, patient organizations, and regulatory authorities. The goal is to treat patients with novel and effective therapies. Overall, Newron Pharmaceuticals SpA is an internationally operating biopharmaceutical company dedicated to researching and developing novel therapies in the field of the central nervous system. Through its innovative research and development activities and close collaboration with experts, institutions, and patient organizations, the company significantly contributes to the advancement of treatment options for neurological disorders. Newron Pharmaceuticals SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Newron Pharmaceuticals SpA's EBIT

Newron Pharmaceuticals SpA's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Newron Pharmaceuticals SpA's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Newron Pharmaceuticals SpA's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Newron Pharmaceuticals SpA’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Newron Pharmaceuticals SpA stock

How much did Newron Pharmaceuticals SpA achieve in EBIT for the current year?

In the current year, Newron Pharmaceuticals SpA has achieved an EBIT of 5.44 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Newron Pharmaceuticals SpA.

How has the EBIT of Newron Pharmaceuticals SpA developed in recent years?

The EBIT of Newron Pharmaceuticals SpA has increased by -146.754% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Newron Pharmaceuticals SpA?

The EBIT of Newron Pharmaceuticals SpA is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Newron Pharmaceuticals SpA pay?

Over the past 12 months, Newron Pharmaceuticals SpA paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Newron Pharmaceuticals SpA is expected to pay a dividend of 0 EUR.

What is the dividend yield of Newron Pharmaceuticals SpA?

The current dividend yield of Newron Pharmaceuticals SpA is .

When does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Newron Pharmaceuticals SpA?

Newron Pharmaceuticals SpA paid dividends every year for the past 0 years.

What is the dividend of Newron Pharmaceuticals SpA?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Newron Pharmaceuticals SpA located?

Newron Pharmaceuticals SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Newron Pharmaceuticals SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Newron Pharmaceuticals SpA from 10/28/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Newron Pharmaceuticals SpA pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Newron Pharmaceuticals SpA in the year 2023?

In the year 2023, Newron Pharmaceuticals SpA distributed 0 EUR as dividends.

In which currency does Newron Pharmaceuticals SpA pay out the dividend?

The dividends of Newron Pharmaceuticals SpA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Newron Pharmaceuticals SpA

Our stock analysis for Newron Pharmaceuticals SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Newron Pharmaceuticals SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.